Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine

Regen BioPharma Advances Towards Breast Cancer Immunotherapy

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine On the 1st of August 2014, Regen BioPharma reported on progress on its therapeutic cancer vaccine dCellVax, which stimulates the immune system of patients to selectively kill tumors. Thomas Ichim, the Chief Scientific Office of Regen BioPharma, said in a statement that ‘we are please to announce …

A new study suggests that HIV patients with a higher level of a particular biomarker may respond more favourably to an experimental immune activating vaccine

New Research Finds a Way to Predict Which HIV Patients Will Respond Better to Future Therapeutic Vaccine

A new study suggests that HIV patients with a higher level of a particular biomarker may respond more favourably to an experimental immune activating vaccine Researchers at St George’s, University of London and Norwegian vaccine company Bionor believe the findings might lead to a customised vaccine for certain patients, which might permit them to come off antiretroviral drugs used to treat …

CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI’S Phase III Head and Neck Cancer Trial into Austria

July 8, 2014 CEL-SCI Corporation today announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Austria is the 14th country to participate in CEL-SCI’s trial which is already active in numerous …

HIV & AIDS: Facts, figures, and vaccines

This month on Vaccine Nation we’re going to be taking a look at HIV/AIDS vaccines. In the coming weeks we will  look at the current generation of HIV vaccines and the different approaches developers are taking in their attempts to defeat this notorious virus. (The infographic may take a few seconds to load) If you have trouble viewing this inforgraphic …

Infographic: Therapeutic Cancer Vaccines – Ones to watch

As Cancer Vaccines Month draws to a close here on Vaccine Nation, we’ve taken a look at the promising cancer vaccines currently in late stage clinical trials. The current crop of cancer vaccines builds upon the lessons learnt from earlier disappointments, and employs new and novel approaches whilst amending endpoints and clinical objectives to better represent the realistic and measurable …

Therapeutic Cancer Vaccines: The failures

Cancer immunotherapy and cancer vaccines were named Science Magazine’s ‘Breakthrough of the Year 2013‘, but whilst the industry continues to be optimistic about the promises of harnessing a patients immune system to treat cancer, it’s hard to ignore the big disappointments that have been recorded in a number of high profile Phase III and II trial failures. Here are just …

Published data supports innovative HSV-2 therapeutic vaccine GEN-003

Genocea Biosciences have announced the publication of preclinical trial results for their investigational therapeutic HSV-2 vaccine. The results, published in Journal of Virology, show that vaccination with GEN-003 and Isconova AB's Matrix-M adjuvant was capable of inducing antigen- and virus-specific immune responses. The vaccine improved outcomes in preclinical models of HSV-2 disease. GEN-003 showed a significant impact on viral shedding …

Lung Cancer vaccine CimaVax-EGF – CIM Cuba

At the recent World Vaccine Congress Washington in April 2012 we had the pleasure of welcoming Dr Diego Venegas Ojeda, as one of our speakers. Dr Venegas is an Oncologist and Assistant Professor of Faculty of Medicine “Alberto Hurtado” at the Universidad Peruana Cayetano Heredia, Committee Immunology Cancer of Latin American Immunology Association. Dr Venegas worked very closely with the …

Therapeutic vaccines– An introduction of Digital Personal Medicine (DPM) with DermaVir

Dr Julianna Lisziewicz, the President, CEO and Vice President of Research, GeneticImmunity joined us at the 12th annual World Vaccine Congress Washington in April 2012 to talk about GeneticImmunity's very interesting take on personalizing vaccines.   Dr Lisziewicz talked us through her views on why we need to personalize DermaVir and other therapeutic vaccines and presented the DPM concept and …

#wvcusa Utilizing Helicobacter pylori platform technology for #vaccine delivery

Dr Barry Marshall, Nobel Prize Winner, Scientific Director at Ondek has delivered a presentation showing his latest research on Helicobacter pylori platform technology (HPPT) and its unique potential as an oral delivery system at the World Vaccine Congress last week. Dr. Marshall described the prospects for a vaccine system using modified Helicobacter pylori which is ingested by drinking and colonizes …